Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Gross Margin: 2013-2025

Historic Gross Margin for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to 67.84%.

  • Coherus Oncology's Gross Margin rose 1293.00% to 67.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 56.31%, marking a year-over-year increase of 3849.00%. This contributed to the annual value of 55.97% for FY2024, which is 1777.00% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Gross Margin is 67.84%, which was up 1.42% from 66.89% recorded in Q2 2025.
  • Coherus Oncology's Gross Margin's 5-year high stood at 90.95% during Q1 2021, with a 5-year trough of 7.60% in Q4 2023.
  • For the 3-year period, Coherus Oncology's Gross Margin averaged around 54.48%, with its median value being 56.14% (2023).
  • In the last 5 years, Coherus Oncology's Gross Margin crashed by 6,108bps in 2023 and then spiked by 4,746bps in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Gross Margin stood at 83.50% in 2021, then crashed by 1,481bps to 68.68% in 2022, then slumped by 6,108bps to 7.60% in 2023, then skyrocketed by 4,746bps to 55.06% in 2024, then surged by 1,293bps to 67.84% in 2025.
  • Its Gross Margin was 67.84% in Q3 2025, compared to 66.89% in Q2 2025 and 65.09% in Q1 2025.